Fibrotic diseases of the genitourinary tract are devastating and incompletely understood pathologies. These diseases include urethral and ureteral strictures, retroperitoneal fibrosis, and Peyronie’s disease. They can contribute to obstructive uropathy and sexual dysfunction. Poor understanding of the pathophysiology of these diseases severely limits our ability to prevent and treat them. Genitourinary fibrotic diseases likely represent related pathologies that share common underlying mechanisms involving wound healing in response to injury. These diseases share the common feature of extracellular matrix abnormalities—such as collagen deposition, transforming growth factor-β accumulation, and dysregulation of collagen maturation—leading to abnormal tissue stiffness. Given the association of many of these diseases with autoimmunity, a systemic pro-inflammatory state likely contributes to their associated fibrogenesis. Herein, we explore the immunologic contribution to fibrogenesis in several fibrotic diseases of the genitourinary system. Better understanding how the immune system contributes to fibrosis in these diseases may improve prevention and therapeutic strategies and elucidate the functions of immunologic contributors to fibrosis in general.
EmingSAMartinPTomic-CanicM. Wound repair and regeneration: mechanisms, signaling, and translation.Sci Transl Med2015;6:1–16
3.
NinanNThomasSGrohensY. Wound healing in urology.Adv Drug Deliv Rev2015;82-83:93–105
4.
LeoniGNeumannPASumaginRDenningTLNusratA. Wound repair: role of immune-epithelial interactions.Mucosal Immunol2015;8:959–68
5.
WynnTAVannellaKM. Macrophages in tissue repair, regeneration, and fibrosis.Immunity2016;44:450–62
6.
BarbulAShaweTRotterSMEfronJEWasserkrugHLBadawySB. Wound healing in nude mice: a study on the regulatory role of lymphocytes in fibroplasia.Surgery1989;105:764–9
7.
BlotnickSPeoplesGEFreemanMREberleinTJKlagsbrunM. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells.Proc Nat Acad Sci1994;91:2890–4
8.
BoyceDEJonesWDRugeFHardingKGMooreK. The role of lymphocytes in human dermal wound healing.Br J Dermatol2000;143:59–65
9.
EfronJEFrankelHLLazarouSAWasserkrugHLBarbulA. Wound healing and T-lymphocytes.J Surg Res1990;48:460–3
10.
BroughtonG2ndJanisJEAttingerCE. The basic science of wound healing.Plast Reconstr Surg2006;117:12S–34S
11.
LeaskAAbrahamDJ. TGF-beta signaling and the fibrotic response.FASEB J2004;18:816–27
12.
DuperretEKNataleCAMonteleonCDahalARidkyTW. The integrin alphav-TGFbeta signaling axis is necessary for epidermal proliferation during cutaneous wound healing.Cell Cycle2016;15:2077–86
13.
KubiczkovaLSedlarikovaLHajekRSevcikovaS. TGF—β—an excellent servant but a bad master.J Transl Med2012;10:183
14.
GongDShiWYiSChenHGroffenJHeisterkampN. TGFb signaling plays a critical role in promoting alternative macrophage activation.BMC Immunol2012;13:1–10
15.
JubanGSaclierMYacoub-YoussefHKernouAArnoldLBoissonCBen LarbiSMagnanMCuvellierSTheretMPetrofBJDesguerreIGondinJMounierRChazaudB. AMPK activation regulates LTBP4-dependent TGF-beta1 secretion by pro-inflammatory macrophages and controls fibrosis in Duchenne muscular dystrophy.Cell Rep2018;25:2163–2176.e6
16.
GauglitzGGKortingHCPavicicTRuzickaTJeschkeMG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies.Mol Med2011;17:113–25
17.
DiegelmannRFEvansMC. Wound healing: an overview of acute, fibrotic and delayed healing.Front Biosci2004;9:283–9
18.
LeaperDAssadianOEdmistonCE. Approach to chronic wound infections.Br J Dermatol2015;173:351–8
19.
EcheverriaCMontorfanoISarmientoDBecerraANunez-VillenaFFigueroaXFCabello-VerrugioCElorzaAARiedelCSimonF. Lipopolysaccharide induces a fibrotic-like phenotype in endothelial cells.J Cell Mol Med2013;17:800–14
20.
FarinaGAYorkMRDi MarzioMCollinsCAMellerSHomeyBRifkinIRMarshak-RothsteinARadstakeTRLafyatisR. Poly(I:C) drives type I IFN- and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis.J Invest Dermatol2010;130:2583–93
21.
LiuRMDesaiLP. Reciprocal regulation of TGF-beta and reactive oxygen species: a perverse cycle for fibrosis.Redox Biol2015;6:565–77
22.
AkhurstRJHataA. Targeting the TGFbeta signalling pathway in disease.Nat Rev Drug Discov2012;11:790–811
23.
XieHFengCFuQSaYLXuYM. Crosstalk between TGF-beta1 and CXCR3 signaling during urethral fibrosis.Mol Cell Biochem2014;394:283–90
24.
GabrielsenJS. Peyronie’s disease: is it genetic or not?Transl Androl Urol2020;9:S262–68
25.
QianAMealsRARajferJGonzalez-CadavidNF. Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture.Urology2004;64:399–404
26.
MartoranaDMarquezACarmonaFDBonattiFAdorniAUrbanMLMaritatiFAccorsi ButtiniEMarvisiCPalmisanoARossiGMTrivioliGFenaroliPManentiLNicastroMIncertiMGianfredaDBaniSFerrettiSCorradiDAlbericiFEmmiGDi ScalaGMoroniGPercesepeAScheelPJJrVermeerEvan BommelEFMartinJVaglioA. A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis.J Allergy Clin Immunol2018;142: 1662–5
27.
PatelDPChristensenMBHotalingJMPastuszakAW. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease.World J Urol2020;38:253–61
28.
BarrattRCBernardJMundyARGreenwellTJ. Pelvic fracture urethral injury in males —mechanisms of injury, management options and outcomes.Transl Androl Urol2018;7:S29–62
29.
CroninCGLohanDGBlakeMARocheCMcCarthyPMurphyJM. Retroperitoneal fibrosis: a review of clinical features and imaging findings.AJR Am J Roentgenol2008;191:423–31
30.
GongTLiuLJiangWZhouR. DAMP-sensing receptors in sterile inflammation and inflammatory diseases.Nat Rev Immunol2020;20:95–112
31.
BragaTTCorrea-CostaMGuiseYFCastoldiAde OliveiraCDHyaneMICenedezeMATeixeiraSAMuscaraMNPerezKRCuccoviaIMPacheco-SilvaAGoncalvesGMCamaraNO. MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages.Mol Med2012;18:1231–9
32.
RicklinDMastellosDCReisESLambrisJD. The renaissance of complement therapeutics.Nat Rev Nephrol2018;14:26–47
33.
VergadiEIeronymakiELyroniKVaporidiKTsatsanisC. Akt signaling pathway in macrophage activation and M1/M2 polarization.J Immunol2017;198:1006–14
34.
DiamondJRKees-FoltsDDingGFryeJERestrepoNC. Macrophages, monocyte chemoattractant peptide-1, and TGF-β1 in experimental hydronephrosis.Am J Physiol1994;266:F926–33
35.
LiuJSBuryMIFullerNJSturmRMAhmadNSharmaAK. Bone Marrow stem/progenitor cells attenuate the inflammatory Milieu following substitution urethroplasty.Sci Rep2016;6:35638
36.
AoubaAGeorgin-LavialleSPagnouxCMartin SilvaNRenandAGalateau-SalleFLe ToquinSBensadounHLarousserieFSilveraSProvostNCandonSSerorRde MenthonMHermineOGuillevinLBienvenuB. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease.Blood2010;116:4070–6
37.
JingRQiTWenCYueJWangGPeiCMaB. Interleukin-2 induces extracellular matrix synthesis and TGF-beta2 expression in retinal pigment epithelial cells.Dev Growth Differ2019;61:410–8
38.
MangieriDCorradiDMartoranaDMalerbaGPalmisanoALibriIBartoliVCarnevaliMLGoldoniMGovoniPAlinoviRBuzioCVaglioA. Eotaxin/CCL11 in idiopathic retroperitoneal fibrosis.Nephrol Dial Transplant2012;27:3875–84
39.
OhtaNKurakamiKIshidaAFurukawaTSuzukiYAoyagiMMatsubaraAIzuharaKKakehataS. Roles of TGF-beta and periostin in fibrosclerosis in patients with IgG4-related diseases.Acta Otolaryngol2013;133:1322–7
40.
VaglioACatanosoMGSpaggiariLMagnaniLPipitoneNMacchioniPPulsatelliLNicastroMBecchiGCorradiDVersariABoiardiLSalvaraniC. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis.Arthritis Rheum2013;65:2469–75
41.
CorradiDMaestriRPalmisanoABosioSGrecoPManentiLFerrettiSCobelliRMoroniGDei TosAPBuzioCVaglioA. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis.Kidney Int2007;72:742–53
42.
RockKLReitsENeefjesJ. Present yourself! By MHC class I and MHC class II molecules.Trends Immunol2016;37:724–37
43.
HashimotoMImSJArakiKAhmedR. Cytokine-mediated regulation of CD8 T-cell responses during acute and chronic viral infection.Cold Spring Harb Perspect Biol2019;11:a028464
44.
ZhuJPaulWE. CD4 T cells: fates, functions, and faults.Blood2008;112:1557–69
45.
Shapiro-ShelefMCalameK. Regulation of plasma-cell development.Nat Rev Immunol2005;5:230–42
46.
ShabsighASourialMBellowsFFMcClungCJayanthiRKielbSBoxGNKnudsenBELeeCTJenkinsLC. Urology. In: BrunicardiFAndersenDKBilliarTR, et al. (eds) Schwartz’s Principles of Surgery. 11th ed.New York: McGraw Hill, 2019
47.
AlwaalABlaschkoSDMcAninchJWBreyerBN. Epidemiology of urethral strictures.Transl Androl Urol2014;3:209–13
48.
WesselsHAngermeierKWElliottSPGonzalezCMKodamaRTPetersonACRestonJRourkeKStoffelJTVanniAVoelzkeBZhaoLSantucciRA. Male urethral stricture: American Urological Association guideline.J Urol2017;197:182
49.
HampsonLAMcAninchJWBreyerBN. Male urethral strictures and their management.Nat Rev Urol2014;11:43–50
50.
CotterKJHahnAEVoelzkeBBMyersJBSmithTG3rdElliottSPAlsikafiNFBreyerBNVanniAJBuckleyJCZhaoLCBroghammerJAEricksonBA, Trauma and Urologic Reconstruction Network of Surgeons (TURNS). Trends in urethral stricture disease etiology and urethroplasty technique from a multi-institutional surgical outcomes research group.Urology2019;130:167–74
51.
GrimesMDTesdahlBASchubbeMDahmoushLPearlmanAMKrederKJEricksonBA. Histopathology of anterior urethral strictures: toward a better understanding of stricture pathophysiology.J Urol2019;202:748–56
52.
SievertKDSelent-StierCWiedemannJGreinerTOAmendBStenzlAFeilGSeiboldJ. Introducing a large animal model to create urethral stricture similar to human stricture disease: a comparative experimental microscopic study.J Urol2012;187:1101–9
53.
LevyACMoynihanMBennettJASullivanTStenslandKBrowneBMFredrickACavalloJAPaguraETua-CaracciaRRieger-ChristKMVanniAJ. Protein expression profiles among lichen sclerosus urethral strictures-can urethroplasty success be predicted.J Urol2020;203:773–8
54.
SiregarSFareniaRSugandiSRoesliRM. Effect of angiotensin II receptor blocker on TGF-beta1, MMP-1, and collagen type I and type III concentration in New Zealand rabbit urethral stricture model.Res Rep Urol2018;10:127–33
55.
NatarajCOliverioMIMannonRBMannonPJAudolyLPAmuchasteguiCSRuizPSmithiesOCoffmanTM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.J Clin Invest1999;104:1693–701
56.
FengHHuangXFuWDongXYangFLiLChuL. A Rho kinase inhibitor (Fasudil) suppresses TGF-beta mediated autophagy in urethra fibroblasts to attenuate traumatic urethral stricture (TUS) through re-activating Akt/mTOR pathway: an in vitro study.Life Sci2021;267:118960
57.
FuDYinJHuangSLiHLiZChongT. Rapamycin inhibits the growth and collagen production of fibroblasts derived from human urethral scar tissue.Biomed Res Int2018;2018:7851327
58.
GulMAltintasEKaynarMBugdayMSGoktasS. The predictive value of platelet to lymphocyte and neutrophil to lymphocyte ratio in determining urethral stricture after transurethral resection of prostate.Turk J Urol2017;43:325–9
59.
OzbirSDegirmentepeRBAtalayHAAlkanICakirSSOtunctemurACanatHL. The role of inflammatory parameters (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-eosinophil ratio) in patients with Peyronie’s disease.Andrology2020;8:348–52
60.
UrkmezATopaktasROzsoyETokucEKutluhanMAArtukIKayarROzturkMI. Is neutrophil to lymphocyte ratio a predictive factor for recurrence of urethral stricture.Rev Assoc Med Bras (1992)2019;65:1448–53
61.
TopaktaşRÜrkmezATokuçEAkyüzMKutluhanMA. Hematologic parameters and neutrophil / lymphocyte ratio in the prediction of urethroplasty success.International Braz J Urol2019;45:369–75
62.
SangkumPYafiFAKimHBouljihadMRanjanMDattaAMandavaSHSikkaSCAbdel-MageedABHellstromWJ. Effect of adipose tissue-derived stem cell injection in a rat model of urethral fibrosis.Can Urol Assoc J2016;10:E175–80
63.
TyritzisSIWiklundNP. Ureteral strictures revisited . . . trying to see the light at the end of the tunnel: a comprehensive review.J Endourol2015;29:124–36
64.
LiuELvLZhanYMaYFengJHeYWenYZhangYPuQJiFYangXWenJG. METTL3/N6-methyladenosine/miR-21-5p promotes obstructive renal fibrosis by regulating inflammation through SPRY1/ERK/NF-kappaB pathway activation.J Cell Mol Med2021;25:7660–74
65.
DretlerSPYoungRH. Stone granuloma: a cause of ureteral stricture.J Urol1993;150:1800–2
66.
MuneerAMacraeBKrishnamoorthySZumlaA. Urogenital tuberculosis—epidemiology, pathogenesis and clinical features.Nat Rev Urol2019;16:573–98
67.
GibertiCGalloFSchenoneMCortesePNinottaG. The bone anchor suburethral synthetic sling for iatrogenic male incontinence: critical evaluation at a mean 3-year followup.J Urol2009;181:2204–8
68.
JerdeTJMellonWSBjorlingDENakadaSY. Evaluation of urothelial stretch-induced cyclooxygenase-2 expression in novel human cell culture and porcine in vivo ureteral obstruction models.J Pharmacol Exp Ther2006;317:965–72
69.
UeshimaEFujimoriMKodamaHFelsenDChenJDurackJCSolomonSBColemanJASrimathveeravalliG. Macrophage-secreted TGF-beta1 contributes to fibroblast activation and ureteral stricture after ablation injury.Am J Physiol Renal Physiol2019;317:F52–64
70.
SharmaAKMauerSMKimYMichaelAF. Interstitial fibrosis in obstructive nephropathy.Kidney Int1993;44:774–88
71.
MathiasCJWelchMJSchwartzDBSpaetheSMNeedlemanP. Differentiation in vivo of the sequential blood cell invasion following ureter obstruction of the rabbit kidney.Int J Rad Appl Instrum B1989;16:25–32
72.
FrangogiannisNG. Regulation of the inflammatory response in cardiac repair.Circ Res2012;110:159–73
73.
HarrisKPSchreinerGFKlahrS. Effect of leukocyte depletion on the function of the postobstructed kidney in the rat.Kidney Int1989;36:210–5
74.
ShappellSBGurpinarTLechagoJSukiWNTruongLD. Chronic obstructive uropathy in severe combined immunodeficient (SCID) mice: lymphocyte infiltration is not required for progressive tubulointerstitial injury.J Am Soc Nephrol1998;9:1008–17
75.
SchmouderRLStrieterRMKunkelSL. Interferon-gamma regulation of human renal cortical epithelial cell-derived monocyte chemotactic peptide-1.Kidney Int1993;44:43–9
76.
IsbelNMHillPAFotiRMuWHurstLAStambeCLanHYAtkinsRCNikolic-PatersonDJ. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation.Kidney Int2001;60:614–25
77.
DiamondJR. Macrophages and progressive renal disease in experimental hydronephrosis.Am J Kidney Dis1995;26:133–40
78.
CrismanJMRichardsLLValachDPFranzoniDFDiamondJR. Chemokine expression in the obstructed kidney.Exp Nephrol2000;9: 241–8
79.
DiamondJRvan GoorHDingGEngelmyerE. Myofibroblasts in experimental hydronephrosis.Am J Pathol1995;146:121–9
80.
LundSAGiachelliCMScatenaM. The role of osteopontin in inflammatory processes.J Cell Commun Signal2009;3:311–22
81.
MarekILichtnegerTCordasicNHilgersKFVolkertGFahlbuschFRascherWHartnerAMenendez-CastroC. Alpha8 Integrin (Itga8) signalling attenuates chronic renal interstitial fibrosis by reducing fibroblast activation, not by interfering with regulation of cell turnover.PLoS ONE2016;11:e0150471
82.
PersonnazJPiccoloEBranchereauMFilliolAPaccoudRMoreauECaliseDRiantEGourdyPHeymesCSchwabeRFDrayCValetPPradereJP. Macrophage-derived HMGB1 is dispensable for tissue fibrogenesis.FASEB Bioadv2019;1:227–45
83.
KimJPadanilamBJ. Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction.Am J Physiol Renal Physiol2011;301:F450–149
84.
WatataniHMaeshimaYHinamotoNYamasakiHUjikeHTanabeKSugiyamaHOtsukaFSatoYMakinoH. Vasohibin-1 deficiency enhances renal fibrosis and inflammation after unilateral ureteral obstruction.Physiol Rep2014;2:e12054
85.
KaeidiASahamsizadehAAllahtavakoliMFatemiIRahmaniMHakimizadehEHassanshahiJ. The effect of oleuropein on unilateral ureteral obstruction induced-kidney injury in rats: the role of oxidative stress, inflammation and apoptosis.Mol Biol Rep2020;47:1371–9
86.
BelmiroCLGoncalvesRGKozlowskiEOWerneckAFTakyiaCMLeiteMJrPavaoMS. Dermatan sulfate reduces monocyte chemoattractant protein 1 and TGF-beta production, as well as macrophage recruitment and myofibroblast accumulation in mice with unilateral ureteral obstruction.Braz J Med Biol Res2011;44:624–33
87.
JiangGTChenXLiDAnHXJiaoJD. Ulinastatin attenuates renal interstitial inflammation and inhibits fibrosis progression in rats under unilateral ureteral obstruction.Mol Med Rep2014;10:1501–8
88.
HosseinianSEbrahimzadeh BideskanAShafeiMNSadeghniaHRSoukhtanlooMShahrakiSSamadi NoshahrZKhajavi RadA. Nigella sativa extract is a potent therapeutic agent for renal inflammation, apoptosis, and oxidative stress in a rat model of unilateral ureteral obstruction.Phytother Res2018;32:2290–8
89.
VaglioAMaritatiF. Idiopathic retroperitoneal fibrosis.J Am Soc Nephrol2016;27:1880–9
90.
Alvarez ArgoteJBauerFAPosteraroAF3rdDasanuCA. Retroperitoneal fibrosis due to B-cell non-Hodgkin lymphoma: responding to rituximab!J Oncol Pharm Pract2016;22:179–85
SwartzRD. Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment.Am J Kidney Dis2009;54:546–53
94.
ScheelPJJrPicciniJRahmanMHLawlerLJarrettT. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis.J Urol2007;178:140; discussion 43–34
95.
ScheelPJJrFeeleyNSozioSM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series.Ann Intern Med2011;154:31–6
96.
HughesDBuckleyPJ. Idiopathic retroperitoneal fibrosis is a macrophage-rich process: implications for its pathogenesis and treatment.Am J Surg Pathol1993;17:482–90
97.
ParumsDVChoudhuryRPShieldsSADaviesAH. Characterisation of inflammatory cells associated with “Idiopathic retroperitoneal fibrosis.”Br J Urol1991;67:564–8
98.
YamashitaKHagaHMikamiYKanematsuANakashimaYKotaniHOgawaOManabeT. Degree of IgG4+ plasma cell infiltration in retroperitoneal fibrosis with or without multifocal fibrosclerosis.Histopathology2008;52:404–9
AdnanSBouraouiAMehtaSBanerjeeSJainSDasguptaB. Retroperitoneal fibrosis; a single-centre case experience with literature review.Rheumatol Adv Pract2019;3:rky050
AkiyamaMKanekoYTakeuchiT. Characteristics and prognosis of ANCA-positive retroperitoneal fibrosis: a systematic literature review.Autoimmun Rev2020;19:102642
103.
KirschbaumBBKoontzWWOlichneyMJ. Association of retroperitoneal fibrosis and interstitial nephritis.Arch Intern Med1981;141: 1361–3
104.
ZaidanMCervera-PierotPde SeigneuxSDahanKFabianiBCallardPRoncoPAucouturierP. Evidence of follicular T-cell implication in a case of IgG4-related systemic disease with interstitial nephritis.Nephrol Dial Transplant2011;26:2047–50
105.
ZenYOnoderaMInoueDKitaoAMatsuiONoharaTNamikiMKasashimaSKawashimaAMatsumotoYKatayanagiKMurataTIshizawaSHosakaNKurikiKNakanumaY. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4.Am J Surg Pathol2009;33:1833–9
106.
KawanoMSaekiTNakashimaH. IgG4-related kidney disease and retroperitoneal fibrosis: an update.Mod Rheumatol2019;29:231–9
107.
UmeharaHOkazakiKMasakiYKawanoMYamamotoMSaekiTMatsuiSSumidaTMimoriTTanakaYTsubotaKYoshinoTKawaSSuzukiRTakegamiTTomosugiNKuroseNIshigakiYAzumiAKojimaMNakamuraSInoueD, Research Program for Intractable Disease by Ministry of Health Labor and Welfare (MHLW) Japan G4 team. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details.Mod Rheumatol2012;22:1–14
AlmeqdadiMAl-DulaimiMPerepletchikovATomeraKJaberBL. Rituximab for retroperitoneal fibrosis due to IgG4-related disease: a case report and literature review.Clin Nephrol Case Stud2018;6:4–10
110.
FujitaEKomineMTsudaHAdachiAMurataSKamataYMinotaSOhtsukiM. Case of H syndrome with massive skin involvement, retroperitoneal fibrosis and Raynaud’s phenomenon with a novel mutation in the SLC29A3 gene.J Dermatol2015;42:1169–71
111.
MorelandRBNehraA. Pathophysiology of Peyronie’s disease.Int J Impot Res2002;14:406–10
SchiavinoDSassoFNuceraEAlciniEGulinoGMilaniAPatriarcaG. Immunologic finidngs in Peyronie’s disease: a controlled study.Urology1997;50:764–8
114.
AtarAKuralAYeniceGComezITugcuV. Role of interleukin-6 and pentraxin 3 as an early marker in Peyronie’s disease.Kaohsiung J Med Sci2017;33:195–200
115.
Garcia RojoEGarcia GomezBSantos-Perez de la BlancaRManfrediCAlonso IsaMMedina PoloJRodriguez AntolinARomero OteroJ. Role of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in Peyronie’s disease: a new diagnostic approach to predict the stage of the disease.Asian J Androl2021;23:325–9
116.
DeanRCLueTF. Peyronie’s disease: advancements in recent surgical techniques.Curr Opin Urol2004;14:339–43
117.
Van de WaterL. Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie’s disease.J Urol1997;157:306–10
118.
CaleyMPMartinsVLO’TooleEA. Metalloproteinases and wound healing.Adv Wound Care (New Rochelle)2015;4:225–34
119.
El-SakkaAIHassobaHMChuiRMBhatnagarRSDahiyaRLueTF. An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression.J Urol1997;158:2284–90
120.
Gonzalez-CadavidNFMageeTRFerriniMQianAVernetDRajferJ. Gene expression in Peyronie’s disease.Int J Impot Res2002;14:361–74
121.
AntoniassiTJuniorFNFSpessotoLCFGuerraLHCamposSSTabogaS. Anti-fibrotic effect of mycophenolate mofetil on Peyronie’s disease experimentally induced with TGF-β.Int J Impot Res2020;32: 201–6
122.
ZimmermannRPFeilGBockCHoeltlLStenzlA. Significant alterations of serum cytokine levels in patients with Peyronie’s disease.Int Braz J Urol2008;34:457–66
123.
Gonzalez-CadavidNFRajferJ. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s disease.Nat Clin Pract Urol2005;2:291–7
124.
PaulisGBrancatoT. Inflammatory mechanisms and oxidative stress in Peyronie’s disease: therapeutic “rationale” and related emerging treatment strategies.Inflamm Allergy Drug Targets2012;11:48–57
125.
MilenkovicUBoeckxBLambrechtsDJankyRHatzichristodoulouGvan RenterghemKGevaertTCellekSBivalacquaTJDe RidderDAlbersenM. Single-cell transcriptomics uncover a novel role of myeloid cells and T-lymphocytes in the fibrotic microenvironment in Peyronie’s disease.Eur Urol Focus2021:S2405-4569(21)00118-8
126.
WillscherMKCwazkaWFNovickiDE. The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie’s disease.J Urol1979;122:34–5
127.
NybergLMJrBiasWBHochbergMCWalshPC. Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens.J Urol1982;128:48–51
128.
RalphDJSchwartzGMooreWPryorJPEbringerABottazzoGF. The genetic and bacteriological aspects of Peyronie’s disease.J Urol1997;157:291–4
129.
LeffellMS. Is there an immunogenetic basis for Peyronie’s disease.J Urol1997;157:295–7
130.
RyuJKKimWJChoiMJParkJMSongKMKwonMHDasNDKwonKDBatboldDYinGNSuhJK. Inhibition of histone deacetylase 2 mitigates profibrotic TGF-beta1 responses in fibroblasts derived from Peyronie’s plaque.Asian J Androl2013;15:640–5
131.
KangDHYinGNChoiMJSongKMGhatakKMinhNNKwonMHSeongDHRyuJKSuhJK. Silencing histone deacetylase 7 alleviates transforming growth factor-beta1-induced profibrotic responses in fibroblasts derived from Peyronie’s plaque.World J Mens Health2018;36:139–46
132.
LylesKWGoldDTNewtonRAParekhSShippKMPieperCFKrishanRCarsonCC3rd. Peyronie’s disease is associated with Paget’s disease of bone.J Bone Miner Res1997;12:929–34
133.
OrdiJSelvaAFonollosaVVilardellMJordanaRTolosaC. Peyronie’s disease in systemic sclerosis.Ann Rheum Dis1990;49:134–5
134.
SimeonCPFonollosaVVilardellMOrdiJSolansRLimaJ. Impotence and Peyronie’s disease in systemic sclerosis.Clin Exp Rheumatol1994;12:464–35
135.
VentimigliaECapogrossoPColicchiaMBoeriLSerinoALa CroceGRussoACapitanioUBrigantiACantielloFMironeVDamianoRMontorsiFSaloniaA. Peyronie’s disease and autoimmunity—a real-life clinical study and comprehensive review.J Sex Med2015;12:1062–9
